CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 13, 2019--
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company
in the discovery and development of TGF-beta superfamily therapeutics
intended to treat serious and rare diseases, today announced that senior
management will present at two upcoming healthcare investor conferences.
Conference Presentation Details:
Event: SVB Leerink 8th Annual Global Healthcare
Date/Time:Thursday, February 28, 2019 at 3:00
Location:New York, NY
Event:Cowen & Co. 39th Annual Healthcare
Date/Time:Monday, March 11, 2019 at 1:30 p.m. ET
A live webcast for the SVB Leerink and Cowen & Co. conference
presentations may be accessed on the Investors/Media page of the
Company's website at www.acceleronpharma.com.
A replay of each webcast will be available approximately two hours after
the event on the Acceleron website.
Acceleron is a clinical-stage biopharmaceutical company dedicated to the
discovery, development, and commercialization of therapeutics to treat
serious and rare diseases. The Company's leadership in the understanding
of TGF-beta biology and protein engineering generates innovative
compounds that engage the body's ability to regulate cellular growth and
Acceleron focuses its research and development efforts in hematologic,
neuromuscular, and pulmonary diseases. In hematology, the Company and
its global collaboration partner, Celgene, are developing luspatercept
for the treatment of chronic anemia in myelodysplastic syndromes,
beta-thalassemia, and myelofibrosis. Acceleron is also advancing its
neuromuscular franchise with two distinct Myostatin+ agents, ACE-083 and
ACE-2494, and a Phase 2 pulmonary program with sotatercept in pulmonary
For more information, please visit www.acceleronpharma.com.
Follow Acceleron on Social Media: @AcceleronPharma
View source version on businesswire.com: https://www.businesswire.com/news/home/20190213005109/en/
Source: Acceleron Pharma
Acceleron Pharma Inc.
Todd James, IRC, 617-649-9393
President, Investor Relations and Corporate Communications
Matt Fearer, 617-301-9557